104 results on '"Satzger I"'
Search Results
2. Sentinel Node Dissection Delays Recurrence and Prolongs Melanoma-Related Survival: An Analysis of 673 Patients from a Single Center with Long-Term Follow-Up
3. Allele frequencies of BRAFV600E mutations are not correlated with treatment outcome in 76 metastatic melanoma patients: FV12
4. Impaired NLRP3 inflammasome expression and function in atopic dermatitis due to Th2 milieu
5. Intermittent BRAF-inhibitor therapy is a feasible option: report of a patient with metastatic melanoma
6. Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma (Nature Medicine, (2019), 25, 12, (1916-1927), 10.1038/s41591-019-0654-5)
7. Are metastatic pathways and the time of progression altered by sentinel node excision?: FV26
8. Relevance of the mTOR Signaling Pathway in Cutaneous Squamous Cell Carcinoma - An Immunohistochemical Study of 58 Immunocompetent and Organ Transplanted Patients: FC-066
9. BRAFV600 Mutations are Highly Consistent in Primary Melanomas and Matched Metastases- an Analysis of 160 Paired Tissue Samples by Real Time PCR and Next-Generation Sequencing: FC-010
10. The price of tumor control: An analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network: FV04/07
11. Die Rolle des m-TOR Signalweges bei kutanen Plattenepithelkarzinomen: FV03/06
12. Die radikale Lymphknotendissektion hat keinen Einfluß auf die Prognose bei Melanompatienten mit geringer Tumorlast im Sentinel-Lymphknoten- eine retrospektive Analyse von 305 Patienten: FV-064
13. Nicht-melanozytäre Hauttumoren treten nach Umstellung der Immunsuppression auf mTor-Inhibitoren seltener auf - eine Fallserie von 12 organtransplantierten Patienten: FV-043
14. Welche Klassifikation des Sentinelbefalls kann die Prognose von Melanompatienten am besten einschätzen?: FV9
15. Analysis of C-KIT expression and KIT gene mutation in human mucosal melanomas: FV15
16. Prognostic significance of histopathological parameters in sentinel nodes of melanoma patients
17. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
18. Erstbeschreibung eines hämatogen-allergischen Kontaktekzems (Baboon) auf Ciclesonid und andere parenterale Kortikosteroide vom Triamcinolontyp: V8
19. Prognostic significance of histopathological parameters in sentinel nodes of melanoma patients
20. Criteria in sentinel nodes of melanoma patients that predict involvement of non-sentinel nodes - Is H&E staining sufficient? (Completion lymphadenectomy is only mandatory for patients with sentinel lymph nodes positive by H&E staining): P21/21
21. Das Auftreten von Autoimmunerkrankungen unter adjuvanter Therapie mit Niedrigdosis-Interferon alpha ist assoziiert mit einer besseren Prognose bei Melanompatienten: P21/22
22. 1104P Nivolumab (NIVO) monotherapy or combination therapy with ipilimumab (NIVO+IPI) in advanced melanoma patients with brain metastases: Real-world evidence from the German non-interventional study NICO
23. The pattern and clinicopathological correlates of programmed death-ligand 1 expression in cutaneous squamous cell carcinoma.
24. Treatment of Advanced Cutaneous Squamous Cell Carcinomas with Epidermal Growth Factor Receptor Inhibitors.
25. Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas.
26. P073. Dermatological follow-up of patients with non melanoma skin cancer after solid organ transplantation switched to an mTOR inhibitor.
27. P90 Remission of iatrogenic Kaposi's sarcoma after switch of immunosuppressive regimen to everolimus in a patient with myasthenia gravis.
28. P25 Prognostic value of SLN biopsy in malignant melanoma of the head/neck in comparison to trunk and extremities.
29. Evaluation of criteria in sentinel nodes of melanoma patients that predict involvement of non-sentinel nodes.
30. Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study.
31. Diagnosis and Differential Diagnosis of Neurological Adverse Events during Immune Checkpoint Inhibitor Therapy.
32. Successful treatment of a metastatic melanoma with Talimogen laherparepvec (T-VEC) in a liver transplant patient.
33. Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.
34. Melanoma-specific survival in patients with positive sentinel lymph nodes: Relevance of sentinel tumor burden.
35. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.
36. Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy-Review of the Literature and Future Outlook.
37. Impact of American Joint Committee on Cancer 8th edition classification on staging and survival of patients with melanoma.
38. Acute progressive neuropathy-myositis-myasthenia-like syndrome associated with immune-checkpoint inhibitor therapy in patients with metastatic melanoma.
39. Combination of denosumab and immune checkpoint inhibition: experience in 29 patients with metastatic melanoma and bone metastases.
40. Risk Factors for Developing Nonmelanoma Skin Cancer after Lung Transplantation.
41. The mTOR-inhibitor Sirolimus decreases the cyclosporine-induced expression of the oncogene ATF3 in human keratinocytes.
42. Treatment-related hemophagocytic lymphohistiocytosis secondary to checkpoint inhibition with nivolumab plus ipilimumab.
43. PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma.
44. Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma.
45. Reinduction of PD1-inhibitor therapy: first experience in eight patients with metastatic melanoma.
46. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity.
47. Clinics, prognosis and new therapeutic options in patients with mucosal melanoma: A retrospective analysis of 75 patients.
48. Effects of mammalian target of rapamycin inhibitors on cytokine production and differentiation in keratinocytes.
49. Characterisation of Prognosis and Invasion of Cutaneous Squamous Cell Carcinoma by Podoplanin and E-Cadherin Expression.
50. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.